Premium priced Tresiba (insulin degludec), Novo Nordisk's ultra-long acting once-daily insulin, appears to have made striking gains in the basal analogues market in India – a segment dominated by Sanofi's Lantus (insulin glargine).
If Lantus, launched more than a decade ago in India, has held strong, reporting robust growth, then Tresiba, which some analysts estimate has an average monthly patient "run
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?